Moderna Inc MRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
-
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
-
23 best-performing stocks of August, as the software industry continues its recovery
-
23 best-performing stocks of August, as the -2-
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech
-
Moderna to Sell $2 Billion Convertible Notes in Private Placement
-
The Treasury, the Fed and the threat to your -2-
Trading Information
- Previous Close Price
- €174.48
- Day Range
- €167.96–171.42
- 52-Week Range
- €19.48–180.56
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 399.24M
- Market Cap
- €67.10B
- Volume/Avg
- 82 / 1,126
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 36.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,700
- Website
- https://www.modernatx.com
Competitors
Valuation
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 9.22 |
Price/Book Value | 11.76 | 1.20 | 1.88 |
Price/Sales | 36.24 | 7.77 | 2.53 |
Price/Cash Flow | — | — | 10.46 |
Price/Earnings
MRNA
BNTX
PFE
Financial Strength
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Quick Ratio | 2.08 | 7.71 | 0.85 |
Current Ratio | 2.29 | 7.85 | 1.27 |
Interest Coverage | −79.21 | — | 2.36 |
Quick Ratio
MRNA
BNTX
PFE
Profitability
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | −23.64% | −5.73% | 8.46% |
Return on Equity (Normalized) | −33.54% | −6.58% | 19.70% |
Return on Invested Capital (Normalized) | −31.72% | −6.97% | 12.66% |
Return on Assets
MRNA
BNTX
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|t&QSps@ | LOCK|!Lz> | $128B | |||
| Moderna Inc
MRNA
| LOCK|c%V?^!F | LOCK|?t | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<JVR!V< | LOCK|>kx<< | $76B | |||
| argenx SE ADR
ARGX
| LOCK|<C@W%Z | LOCK|JDP | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%jc>p$ | LOCK|$Q | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$^XBQlH | LOCK|wJmFS | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|c>&s>@j^ | LOCK|&vmM | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|SHnVWs | LOCK|^p | $24B | |||
| Incyte Corp
INCY
| LOCK|>FP%%l% | LOCK|?^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%R?qQRw | LOCK|f% | $15B |
United States